Background: The study aims to understand the Ayushman Bharat- Pradhan Mantri Jan Arogya Yojana (AB PM-JAY) and Mahatma Jyotirao Phule Jan Arogya Yojana (MJPJAY)health scheme awareness, challenges faced by the scheme beneficiaries, facilitators and out-of-pocket expenditure (OOPE) for cancer treatment at Tata Memorial Hospital, Mumbai.

Methods: We conducted an observational cross-sectional study approved by the Tata Memorial Centre Ethics Committee. We collected data by interviewing participants through a structured questionnaire.

Results: Out of 515 participants, 489 (95 %) were beneficiaries (patients/caregivers) of the schemes, 15 (2.9 %) MJPJAY staff, 6 (1.1 %) medical social workers (MSW), and 5 (1.0 %) AB PM-JAY staff. Of the 489 beneficiaries, only 162 (33.1 %) were aware of the scheme. Most patients were satisfied with the benefits of the scheme; of the 83 (17 %) who were dissatisfied, 30 (36 %) cited incomplete coverage at a 95 % Confidence Interval (CI) [0.26-0.46] and 19 (23 %) 95 % CI [0.14-0.32] cited OOPE as the reason for dissatisfaction. Participants opined a need to increase package coverage of cancer treatment and essential investigations. The beneficiaries highlighted delays in the approval process and technical issues of the scheme as potential areas of improvement.

Conclusion: Government health schemes are effective in improving treatment completion without impoverishment and have the potential to improve treatment outcomes and cancer survival. Study results indicate the need to increase awareness about these schemes in the general population, improving the health benefit packages for cancer treatment, with inclusion investigations, supportive care, nutritional care, palliative care, immunotherapy, chemotherapy drugs, targeted therapy, bone marrow transplantation, and hormonal therapy.

Policy Summary: Government-funded health schemes are effective in reducing impoverishment related to healthcare costs and promoting Universal Health Coverage. However, periodic review of the breadth of coverage as well as feasibility of completing treatment using these packages is necessary to eliminate out-of-pocket expenditure and facilitate treatment completion.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jcpo.2025.100564DOI Listing

Publication Analysis

Top Keywords

cancer treatment
16
health schemes
12
tata memorial
12
government-funded health
8
treatment
8
treatment tata
8
memorial centre
8
jan arogya
8
arogya yojana
8
out-of-pocket expenditure
8

Similar Publications

Historical studies performed nearly a century ago using mouse skin models identified two key steps in cancer evolution: initiation, a likely mutational event, and promotion, driven by inflammation and cell proliferation. Initiation was proposed to be permanent, with promotion as the critical rate-limiting step for cancer development. Here, we carried out whole genome sequencing to demonstrate that initiated cells with thousands of mutagen-induced mutations can persist for long periods and are not removed by cell competition or by immune intervention, thus mimicking the persistence of cells with cancer driver mutations in normal human tissues.

View Article and Find Full Text PDF

A novel pheophorbide derivative, trimethyl-152-[L-aspartyl]pheophorbide a was synthesised and investigated for anti-tumor activity. The prepared photosensitizer had good absorption in the phototherapeutic window and high ROS yields. It exhibited excellent phototoxicity higher than reference compound m-THPC when irradiated by 650 nm light in vitro, and obvious photodynamic anti-tumor effect in vivo.

View Article and Find Full Text PDF

Pituitary neuroendocrine tumors (PitNETS) are common intracranial tumors, but extrasellar or ectopic PitNETS are very rare and supposed to originate from some pituitary remnants. They are mostly found in sphenoidal sinus. But particularly, ectopic clival PitNETS are highly aggressive and can cause bone invasion and can be misdiagnosed as other lesions of the skull base such as chordomas.

View Article and Find Full Text PDF

Background: Breast cancer is the second most common cancer in women worldwide. Treatments for this disease often result in side effects such as pain, fatigue, loss of muscle mass, and reduced quality of life. Physical exercise has been shown to effectively mitigate these side effects and improve the quality of life in patients with breast cancer.

View Article and Find Full Text PDF

This study aimed to assess the efficacy and safety of combining cemiplimab, an anti-PD1 antibody, with isatuximab, an anti-CD38 antibody, in relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL). The hypothesis was that CD38 blockade could enhance the antitumor activity of PD1 inhibitors. Eligible patients received cemiplimab (250 mg on days 1 and 15) and isatuximab (10 mg/kg on days 2 and 16) intravenously every four weeks for six cycles.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!